Researchers at Rush have identified biomarkers that indicate which hip replacement patients are likely to suffer from destruction of bone tissue.
Osteoarthritis (OA) is one of the most common causes of chronic pain in the world. More than 30 million people in the United States alone suffer from OA, which can affect any moveable joint of the body, including the knees, hips, and hands. OA normally manifests itself as a breakdown of joint tissues, including degradation of cartilage.
Rush is helping lead a new health research accelerator that has launched in the Chicago area with nearly $35 million in funding from the NIH.
Stem cell treatments have potential to transform medicine. Experts in cancer, neurosurgery, orthopedics and pediatrics discuss the possibilities.
Rush researcher Susan Chubinskaya, PhD, is helping lead a study that aims to make space travel easier on astronauts, while providing insights for the rest of us here on Earth.
The number of cancer clinical trials at Rush doubled last year — from around 30 in early 2015 to nearly 150 by the end of 2016. And the focus of the research has broadened.
A study has found that the gene mutation that puts many black people at risk for chronic kidney disease requires higher than normal levels of a protein called suPAR to trigger the onset and progression of the disease.
A Rush study shows for the first time how dying cells ensure they will be replaced, and suggests a new approach to shrinking cancerous tumors.
Sarah Ailey PhD, APHN, is studying ways to improve social skills of people with intellectual disabilities in order to help them avoid harmful situations.
Two studies are using smart glasses to assess behavior of children with autism in order to find ways to enhance their interactions with others.